MNPR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Monopar Therapeutics Inc (MNPR) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. The lack of positive financial performance, absence of significant trading trends, and no clear technical or proprietary trading signals suggest holding off on this stock for now.
The MACD is positive and contracting, indicating a potential weakening of bullish momentum. RSI is neutral at 60.529, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level (55.652) with resistance at 59.323 and support at 51.981.
NULL identified. No recent news or significant trading trends from hedge funds or insiders.
No recent news or events to drive positive sentiment.
The company's Q4 2025 financials show no revenue growth (0% YoY), a significant drop in net income (-52.40% YoY), and a sharp decline in EPS (-72.65% YoY). Gross margin remains at 0%.
No analyst rating or price target changes available.
